GlaxoSmithKline plc (ADR) (GSK), Novartis AG (ADR) (NVS): This Company’s Debt Might Be a Concern

Page 1 of 2

GlaxoSmithKline plc (ADR) (NYSE:GSK) has been accused of making illegal payments to Chinese doctors and government officials by siphoning them through travel agencies. If these allegations are substantiated — Glaxo officials at the highest levels have acknowledged that company executives might have broken the law — they could have serious ramifications for the firm’s future. By some accounts, however, these entanglements are simply the price of doing business, something that companies move beyond in the course of things.

But, does GlaxoSmithKline plc (ADR) (NYSE:GSK) enjoy enough financial strength to withstand these pressures? A study of its numbers seemingly does not indicate that is the case; this United Kingdom-based company is carrying too much debt to slide though rough times.

GlaxoSmithKline plc (ADR) (NYSE:GSK)Value investors carefully scrutinize a company’s debt/equity ratio. And GlaxoSmithKline plc (ADR) (NYSE:GSK)’s debt/equity ratio (for the most recent quarter) was 253.66, clearly high enough to set off warning signals, even if it does not mean that this pharmaceutical company stands in eminent danger of becoming “insolvent.” Also troubling, Glaxo’s revenue and earnings have been not been rising, an indication that any funds it is accumulating through borrowing have not been utilized in ways that spurred growth. Its year over year quarterly earnings growth (as of June 30, 2013) was (26.50)% and its year to quarterly revenue growth for the same period was (2.50)%.

And not surprisingly, the credit rating agencies have taken note of GlaxoSmithKline plc (ADR) (NYSE:GSK)’s debt. Earlier this summer, Moody’s cut the outlook on Glaxo’s long-term A1 rating to “negative” from “stable.” In making that move, it cited concerns not only about the company’s debt, but also about massive legal settlements it has been obliged to pay. These payments evolved from marketing strategies designed to pump up sales of its diabetes drug Avandia and its antidepressant Wellbutrin rather than from the Chinese “scandal.”

And GlaxoSmithKline plc (ADR) (NYSE:GSK) recently received other troubling news. India’s Intellectual Property Appellate Board (IPAB) revoked the patent that it held on its breast cancer drug Tykerg, a salt form of lapatinib. The challenge that resulted in this judgment came not from an Indian company, but from the Indian unit of the German drug maker Fresenius Kabi.

Decisions of this type might become more common in the future and greatly impede the potential of Glaxo and other pharmaceutical companies to expand their sales into developing countries.

Some alternatives

If investors prefer a European pharmaceutical company to an American one, but are leery of GlaxoSmithKline plc (ADR) (NYSE:GSK), they do have two alternatives: Novartis AG (ADR) (NYSE:NVS) and AstraZeneca plc (ADR) (NYSE:AZN).

However, while some of the fundamentals these firms have might be more impressive than GlaxoSmithKline plc (ADR) (NYSE:GSK)’s, they are hardly stellar. Novartis AG (ADR) (NYSE:NVS) had a debt/equity ratio (for the most recent quarter) of 27.10, hardly the 1.00 or less that is considered optimum. And its year over year revenue growth for the quarter ending on March 31, 2013, was only 1.10% while quarterly earnings growth for the same period was (5.00)%, hardly a reflection of robust profitability.

But, it is sometimes difficult to predict future results based on the past or even the present performances, and there is reason to believe that Novartis AG (ADR) (NYSE:NVS)’ prospects might be brighter than its current fundamentals would indicate. It continues to lead the industry with 56 new approvals in the U.S., Europe, Japan, and China since 2007. In 2012 alone, the Pharmaceuticals division received nine approvals or positive recommendations to date. One of the most promising new additions to Norvatis’ catalog is Afinitor, an oncology drug. Analysts predict that it has the potential to exceed sales of $2 billion for the treatment of breast cancer alone by 2017.

The United Kingdom-based AstraZeneca plc (ADR) (NYSE:AZN), meanwhile, had an unimpressive debt/equity ratio (for the most recent quarter) of 45.42. And for the quarter ending on March 31, 2013, its year over year quarterly revenue decline was 13.10% and its quarterly earnings fall was an even more troublesome 37.80%.

Page 1 of 2

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The World’s Most Famous Circuses

Best Hair Stylists

Most Popular NASCAR Drivers

The Best Romance Movies of all Time

The Most Wanted Drug Lords

The Oldest Money Managers

The Greatest Directors in the World

Largest Animals in the World

World’s Most Expensive Desserts

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Best Travel Destinations in Australia

World’s Most Expensive Musical Instruments

World’s Most Famous Animals

Most Expensive Cakes in the World

Most Expensive Kosher Champagne in the World

Most Expensive Kosher Wine in the World

The Most Surprisingly Dark Fairy Tales

Most Popular Travel Destinations in Asia

The 10 Most Expensive Dresses Ever Worn to the Oscars

World’s Most Visited Art Museums

Best Countries for Photographers to Work in

Best Paid Jobs in the Film Industry

The Most Renowned Recovered Paintings Ever

Child Stars That Turned out Just Fine

Books That Were Banned in the Past Century

World’s Richest Dancers

Best Remedies against Bad Breath

Foods That Improve Your Skin Texture

Best-Selling Children’s Books of all Time

Foods That Boost Your Libido

Best-Selling Books of all Time

The Most Expensive Academy Awards Jewelry in History

Most Expensive Japanese Restaurant In New York City

The Best B-Boy Movies

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!